A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Results of the international IROCAS study.

Fiche publication

Date publication

octobre 2026

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Bennouna J, André T, Martin E, Cremolini C, Gill S, Asmis T, Kavan P, Mitry E, Hiret S, Mineur L, Artru P, Perret C, Bouché O, Touchefeu Y, Goldenberg B, Dupuis O, Lonardi S, Chibaudel B, Castanié H, Coutzac C, Bauguion L, Guardiola E, Benmaziane A, Barrière J, Chen E, Simmet V, Allegrini G, Marmorino F, Pezzella V, Monard L, Campion L, O'Callaghan C, Taieb J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42927853

Résumé

Patients with pT4 and/or pN2 stage III colon cancer remain at high risk of recurrence despite oxaliplatin-based adjuvant chemotherapy. We evaluated whether intensification with modified FOLFIRINOX improved outcomes compared with modified FOLFOX6.